Log in
NASDAQ:DTIL

Precision BioSciences Stock Forecast, Price & News

$5.95
0.00 (0.00 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$5.84
Now: $5.95
$6.04
50-Day Range
$4.65
MA: $5.95
$7.20
52-Week Range
$4.45
Now: $5.95
$23.67
Volume1.71 million shs
Average Volume601,273 shs
Market Capitalization$311.48 million
P/E RatioN/A
Dividend YieldN/A
Beta1.27
Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, is an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and CD20, BCMA, and CLL-1, CAR T cell therapies targeting the tumor antigens. The Food segment develops food and nutrition products; and pre-breeding materials, a gene edited crop intermediate that could be integrated into breeding program and use in producing new crop varieties. The company has development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DTIL
CUSIPN/A
CIKN/A
Phone919-314-5512

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.24 million
Book Value$2.72 per share

Profitability

Net Income$-92,880,000.00
Net Margins-519.93%

Miscellaneous

Employees127
Market Cap$311.48 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$5.95
0.00 (0.00 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DTIL News and Ratings via Email

Sign-up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Precision BioSciences (NASDAQ:DTIL) Frequently Asked Questions

How has Precision BioSciences' stock been impacted by Coronavirus (COVID-19)?

Precision BioSciences' stock was trading at $6.49 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DTIL shares have decreased by 8.3% and is now trading at $5.95.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Precision BioSciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Precision BioSciences
.

When is Precision BioSciences' next earnings date?

Precision BioSciences is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Precision BioSciences
.

How were Precision BioSciences' earnings last quarter?

Precision BioSciences Inc (NASDAQ:DTIL) issued its quarterly earnings data on Thursday, August, 13th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.59) by $0.04. Precision BioSciences had a negative return on equity of 81.82% and a negative net margin of 519.93%.
View Precision BioSciences' earnings history
.

What price target have analysts set for DTIL?

5 analysts have issued 12-month price targets for Precision BioSciences' shares. Their forecasts range from $18.00 to $21.00. On average, they anticipate Precision BioSciences' share price to reach $19.33 in the next year. This suggests a possible upside of 224.9% from the stock's current price.
View analysts' price targets for Precision BioSciences
.

Are investors shorting Precision BioSciences?

Precision BioSciences saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 1,710,000 shares, a decrease of 11.4% from the August 15th total of 1,930,000 shares. Based on an average daily volume of 598,600 shares, the days-to-cover ratio is presently 2.9 days. Approximately 4.5% of the company's stock are short sold.
View Precision BioSciences' Short Interest
.

Who are some of Precision BioSciences' key competitors?

What other stocks do shareholders of Precision BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), Alector (ALEC), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO), Micron Technology (MU), InVitae (NVTA) and Crispr Therapeutics (CRSP).

Who are Precision BioSciences' key executives?

Precision BioSciences' management team includes the following people:
  • Mr. Matthew R. Kane, Co-Founder, CEO, Pres & Director (Age 42)
  • Dr. Derek Jantz Ph.D., Co-founder, Chief Scientific Officer & Director (Age 43)
  • Dr. Jefferson J. Smith Ph.D., Co-Founder & CTO
  • Mr. Abid Ansari, Chief Financial Officer (Age 41)
  • Ms. Molly Lukes PHR, SHRM-CP, Director of HR

When did Precision BioSciences IPO?

(DTIL) raised $126 million in an IPO on Thursday, March 28th 2019. The company issued 7,900,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays served as the underwriters for the IPO.

What is Precision BioSciences' stock symbol?

Precision BioSciences trades on the NASDAQ under the ticker symbol "DTIL."

Who are Precision BioSciences' major shareholders?

Precision BioSciences' stock is owned by many different institutional and retail investors. Top institutional investors include venBio Partners LLC (5.38%), ArrowMark Colorado Holdings LLC (4.32%), FMR LLC (2.33%), CHI Advisors LLC (1.85%), CHI Advisors LLC (1.85%) and Adams Chetwood Wealth Management LLC (1.03%). Company insiders that own Precision BioSciences stock include Christopher Heery, Global Strategic Fund Venbio and Tony Dung Ling Yao.
View institutional ownership trends for Precision BioSciences
.

Which institutional investors are selling Precision BioSciences stock?

DTIL stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, venBio Partners LLC, Bailard Inc., Adams Chetwood Wealth Management LLC, PDT Partners LLC, and UBS Group AG.
View insider buying and selling activity for Precision BioSciences
.

Which institutional investors are buying Precision BioSciences stock?

DTIL stock was purchased by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Principal Financial Group Inc., Principal Financial Group Inc., Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., Swiss National Bank, Thomasville National Bank, and Bank of New York Mellon Corp. Company insiders that have bought Precision BioSciences stock in the last two years include Christopher Heery, Global Strategic Fund Venbio, and Tony Dung Ling Yao.
View insider buying and selling activity for Precision BioSciences
.

How do I buy shares of Precision BioSciences?

Shares of DTIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Precision BioSciences' stock price today?

One share of DTIL stock can currently be purchased for approximately $5.95.

How big of a company is Precision BioSciences?

Precision BioSciences has a market capitalization of $311.48 million and generates $22.24 million in revenue each year. The company earns $-92,880,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Precision BioSciences employs 127 workers across the globe.

What is Precision BioSciences' official website?

The official website for Precision BioSciences is www.precisionbiosciences.com.

How can I contact Precision BioSciences?

Precision BioSciences' mailing address is 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701. The company can be reached via phone at 919-314-5512 or via email at [email protected]

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.